iPLEDGE program

The iPLEDGE program is a U.S. government-safe registry designed to prevent women who are pregnant or may become pregnant from using the acne medication isotretinoin due to its serious birth defect risks. Patients, healthcare providers, and pharmacies must register and follow specific guidelines, including regular pregnancy testing and contraception use. The objective is to ensure that isotretinoin is prescribed and dispensed responsibly, minimizing the chance of fetal exposure. The program maintains detailed records and communication among all parties involved to promote safe treatment and protect unborn children from potential harm.